SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 263.24 |
Enterprise Value ($M) | 207.02 |
Book Value ($M) | 116.74 |
Book Value / Share | 2.26 |
Price / Book | 2.26 |
NCAV ($M) | 92.20 |
NCAV / Share | 1.78 |
Price / NCAV | 2.86 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.58 |
Return on Assets (ROA) | -0.53 |
Return on Equity (ROE) | -0.71 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 6.82 |
Current Ratio | 6.82 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 134.03 |
Assets | 158.57 |
Liabilities | 41.83 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -86.46 |
Net Income | -82.44 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -66.72 |
Cash from Investing | 16.35 |
Cash from Financing | 71.93 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | T. Rowe Price Investment Management, Inc. | 12.90 | 69.96 | |
13G/A | Bb Biotech Ag | 16.50 | 58.39 | |
13D/A | Versant Venture Capital VI, L.P. | 8.40 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
72,734 | 404,260 | 17.99 | |
43,766 | 250,305 | 17.49 | |
88,685 | 492,873 | 17.99 | |
197,257 | 817,043 | 24.14 | |
(click for more detail) |
Similar Companies | |
---|---|
AVXL – Anavex Life Sciences Corp. | BBIO – BridgeBio Pharma, Inc. |
BCRX – BioCryst Pharmaceuticals, Inc. | BEAM – Beam Therapeutics Inc. |
BIIB – Biogen Inc. |
Financial data and stock pages provided by
Fintel.io